Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LSCI Evaluation with Capsaicin and AITC
NCT06809569Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2023
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial, sponsored by Merck & Co. Primary endpoints: Mean Dermal Blood Flow in the Region of Interest, Area Under the Curve of Mean Dermal Blood Flow (0-20 min) and 1 more. Started Sep 2023; status: completed.
Beyond the preview
Go deeper on NCT06809569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809569.